Price T Rowe Associates Inc Adverum Biotechnologies, Inc. Call Options Transaction History
Price T Rowe Associates Inc
- $816 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ADVM
# of Institutions
5Shares Held
3.6MCall Options Held
0Put Options Held
0-
Tcg Crossover Management, LLC Palo Alto, CA2.01MShares$13.8 Million2.99% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.07MShares$7.34 Million0.79% of portfolio
-
Versant Venture Management, LLC San Francisco, CA507KShares$3.48 Million9.99% of portfolio
-
Pinz Capital Management, LP New York, NY15.7KShares$107,7020.03% of portfolio
-
American Portfolios Advisors Holbrook, NY1.15KShares$7,8890.0% of portfolio
About Adverum Biotechnologies, Inc.
- Ticker ADVM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 99,333,600
- Market Cap $681M
- Description
- Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...